Tags : Intractable

Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to

Shots: Orionis to receive research funding, convertible notes, clinical milestones along with royalties while Novartis gets access to Orionis’ Allo-Glue technology platform for designing novel therapies like protein degraders across multiple therapeutic areas The collaboration will combine Novartis’ expertise in drug discovery and development with Orionis’ innovative technologies for identifying and prioritizing new targets at […]Read More